相关实验视频

Updated: Jun 28, 2025

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

用IL-17A抑制剂治疗泛性性牛皮的快速和持续的解决需要高度坚持:在现实生活环境中进行96周的分析

Kun Hu^{1,2,3,4,5,6,7}, Yijie Liu^{1,2,3,4,5,6,7}, Yizhang Liu^{1,2,3,4,5,6,7}

¹The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

International journal of dermatology

|April 18, 2024

概括

干白素 (IL) -17A抑制剂有效地长期治疗泛性性牛皮 (GPP). 高剂量药物坚持显著改善皮肤清除,并减少GPP患者的发作.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

泛性性牛皮 (GPP) 是一种罕见的,严重的,可能危及生命的皮肤病.
长期管理GPP往往需要持续的治疗干预.
干白素-17A (IL-17A) 抑制剂是一种用于治疗炎症疾病的生物药物.

研究的目的:

评估IL-17A抑制剂的疗效和安全性,特别是secukinumab和ixekizumab,在96周的时间内管理GPP.
评估药物坚持对GPP患者治疗结果的影响.
确定IL-17A抑制剂在实现和维持皮肤清除方面的长期有效性.

主要方法:

对18名GPP患者的回顾性分析,这些患者接受了secukinumab (n=13) 或ixekizumab (n=5) 的治疗.
主要终点:在通用性皮质银病区域和严重性指数 (GPPASI) 评分中实现≥90%或100%改善的患者的百分比.
通过药物占有率 (MPR) 评估药物坚持;对96周的爆发和安全信号的分析.

主要成果:

使用观察结果 (AO) 方法观察到高比例的GPPASI 90 (87%) 和GPPASI 100 (67%) 反应.
平均GPPASI从基线改善到96周达到96.3% (AO方法).
较高的坚持 (MPR ≥80%) 与实现GPPASI 100响应 (100%对38%,P<0.05) 有显著的关联;较低的坚持与火焰的增加相关.

结论:

IL-17A抑制剂在GPP患者中显示出有效和持续的临床改善.
高剂量药物坚持对于实现长期皮肤清除和管理GPP的复发性至关重要.
在这个队列中,在96周内使用IL-17A抑制剂时,没有发现新的安全问题.

关键词:

坚持性坚持性有效性有效性.一般化的性牛皮.在这里,我们来看一下ixekizumabb.这是一个长期的长期的长期.干燥的干燥的干燥

更多相关视频

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...